These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37297945)

  • 1. Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study.
    Parlati L; Marcin K; Terris B; Vallet-Pichard A; Corouge M; Hollande C; Sogni P; Mallet V; Pol S
    J Clin Med; 2023 May; 12(11):. PubMed ID: 37297945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.
    Kawano M; Yano Y; Yamamoto A; Yasutomi E; Inoue Y; Kitadai J; Yoshida R; Matsuura T; Shiomi Y; Ueda Y; Kodama Y
    Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
    Sawada K; Hayashi H; Nakajima S; Hasebe T; Fujiya M; Okumura T
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1042-1048. PubMed ID: 31752049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study.
    Gualano G; Zace D; Mosti S; Mencarini P; Musso M; Libertone R; Cerva C; Goletti D; Rianda A; Del Nonno F; Falasca L; Palmieri F
    Infect Dis Rep; 2023 Nov; 15(6):735-746. PubMed ID: 38131879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
    Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
    JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatobiliary and Pancreatic Adverse Events.
    Zhang HC; Wang LS; Miller E
    Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
    Xu Z; Hao X; Yang K; Wang Q; Wang J; Lin L; Teng F; Li J; Xing P
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3081-3089. PubMed ID: 34982222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver biopsy findings in patients on immune checkpoint inhibitors.
    Cohen JV; Dougan M; Zubiri L; Reynolds KL; Sullivan RJ; Misdraji J
    Mod Pathol; 2021 Feb; 34(2):426-437. PubMed ID: 32884128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-induced autoimmune-like liver injury].
    Weber S
    Inn Med (Heidelb); 2024 Apr; 65(4):334-339. PubMed ID: 38374310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of liver biopsy in the era of clinical prediction scores for "drug-induced liver injury" (DILI): experience of a tertiary referral hospital.
    Costa-Moreira P; Gaspar R; Pereira P; Lopes S; Canão P; Lopes J; Carneiro F; Macedo G
    Virchows Arch; 2020 Oct; 477(4):517-525. PubMed ID: 32377873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
    Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
    Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
    De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
    JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.
    Hisamochi A; Kage M; Ide T; Arinaga-Hino T; Amano K; Kuwahara R; Ogata K; Miyajima I; Kumashiro R; Sata M; Torimura T
    J Gastroenterol; 2016 Jun; 51(6):597-607. PubMed ID: 26519284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
    Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
    Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial.
    Wang JB; Huang A; Wang Y; Ji D; Liang QS; Zhao J; Zhou G; Liu S; Niu M; Sun Y; Tian H; Teng GJ; Chang BX; Bi JF; Peng XX; Xin S; Xie H; Ma X; Mao YM; Liangpunsakul S; Saxena R; Aithal GP; Xiao XH; Zhao J; Zou Z
    Aliment Pharmacol Ther; 2022 May; 55(10):1297-1310. PubMed ID: 35362188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study.
    Jiang Y; Lv M; Jin Z; Wu Y; Li X; Zhang N
    Br J Clin Pharmacol; 2024 Jul; ():. PubMed ID: 39040025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
    Sisi M; Vitale G; Fusaroli M; Riefolo M; Giunchi V; D'Errico A; Ardizzoni A; Raschi E; Gelsomino F
    JTO Clin Res Rep; 2023 Sep; 4(9):100563. PubMed ID: 37745898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update.
    Björnsson ES
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.